Revolade
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease caused by antibodies against platelet glycoproteins…
_ Die aplastische Anämie (AA) beruht auf einer zu etwa 80% autoimmun bedingten, dezienten Produktion von Knochenmarkszellen und…
_ Die aplastische Anämie (AA) beruht auf einer zu etwa 80% autoimmun bedingten, dezienten Produktion von Knochenmarkszellen und…
Eltrombopag (Revolade®), an orally active thrombopoietin receptor agonist, fills an important formerly unmet clinical need in…
Too many potentially life-threatening adverse effects, including hepatic decompensation and thromboembolic complications.
The introduction of thrombopoietin receptor (TPO-R) agonists, also called TPO mimetics, has offered new treatment possibilities…
On 11th March 2010, the European Commission issued a marketing authorization valid throughout the European Union for Revolade for…
Eltrombopag (Revolade®) is an orally bioavailable, low molecular weight, synthetic nonpeptide thrombopoietin receptor agonist…
When corticosteroid therapy, immunoglobulin and splenectomy fail to control chronic idiopathic thrombocytopenic purpura and the…
Platelets play a pivotal role in maintaining hemostatic competence. Thrombocytopenia, irrespective of its etiology, is associated…